Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This includes Wegovy (the weight-loss dose of Ozempic, or semaglutide) and Mounjaro ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.